Revenue Growth 960% Year Over Year

Reports Profitable Fourth Quarter
Record Net Revenue of $128.6 Million, Up 75% from Prior Quarter 
Revenue for Adult-use Cannabis of $18.5 Million, Up 158% from Prior Quarter
Provides Fiscal Year 2020 Outlook

These shares are on fire Three analysts rate the company a STRONG BUY with two rating APHA a MODERATE BUY.

Aphria being one of the few marijuana companies turning a profit this company leads the pack.  Serious investors need to place these shares on their BUY LIST.

LEAMINGTON, ON, Aug. 1, 2019 /CNW/ - Aphria Inc. ("Aphria (APHA)" or the "Company") (TSX: APHA and NYSE: APHA) today reported its results for the fourth quarter and fiscal year ended May 31, 2019. All amounts are expressed in thousands of Canadian dollars, unless otherwise noted and except for per gram, kilogram, kilogram equivalents, and per share amounts.

Products   Website  Oils  Analysts Ratings

"It's a new day at Aphria. Our team's solid execution across key areas of our business resulted in strong adult-use revenue growth and a profitable fourth quarter," stated Irwin D. Simon. "Over the last six months, our organization identified immediate priorities to help generate substantial progress near-term and long-term. We built upon existing business fundamentals and capabilities, streamlined processes, strengthened governance, and focused on building brand awareness. Together, we have nurtured an entrepreneurial culture of accountability through data-driven decision-making for value creation in the global medical and adult-use cannabis industry.  Today's Aphria has a stronger foundation for long-term growth and success." Operating Highlights

Aurora Cannabis Hits Wall With Rev Miss - Wall St Hits Stock -  NYSE Canopy Growth  - Analyst Says BUY 

• Net revenue of $128.6 million in the fourth quarter, an increase of 75% from prior quarter and 969% from prior year.
• Revenue for adult-use cannabis of $18.5 million in the fourth quarter, up 158% from prior quarter.
• Net income of $15.8 million and adjusted EBITDA of $0.2 million in the fourth quarter.
• Adjusted EBITDA from cannabis operations of $1.9 million in the fourth quarter.
• Closed a 5.25% convertible senior notes offering for net proceeds of over US $335 million.
• Ended quarter with a strong balance sheet and liquidity, including $571 million of cash, cash equivalents and liquid marketable securities, to fund planned Canadian and International growth.
• Settlement of Green Growth Brands takeover bid resulting in $50 million cash received and an additional $39 million to be received in November.
• Planted more than 200,000 plants in the new expanded area of Aphria One cultivation.
• On-track for annual production capacity of 255,000 kilograms when all facilities are fully licensed.
• Granted the maximum amount of lots within the German tender process, a total of five, and is the only licensed producer in Germany with the permission to grow all three strains of medical cannabis approved by the German Federal Institute for Drugs and Medical Devices.
• Introduced a CBD-based nutraceutical product line for the German market.
• Enhanced the executive team with appointment of several key positions.